137 related articles for article (PubMed ID: 34684024)
1. Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a Mouse Model of Advanced Atherosclerosis.
Claesen K; Roth L; Mertens JC; Hermans K; Sim Y; Hendriks D
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34684024
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals.
Claesen K; Sim Y; Basir S; De Belder S; van den Keybus T; Van Edom G; Stoffelen H; De Keulenaer GW; Bosmans J; Bringmans T; De Meester I; Hendriks D
J Thromb Haemost; 2023 May; 21(5):1266-1273. PubMed ID: 36740042
[TBL] [Abstract][Full Text] [Related]
3. Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Claesen K; Mertens JC; Basir S; De Belder S; Maes J; Bosmans J; Stoffelen H; De Meester I; Hendriks D
Clin Ther; 2021 May; 43(5):908-916. PubMed ID: 33910760
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
Roth L; Rombouts M; Schrijvers DM; Martinet W; De Meyer GR
Vascul Pharmacol; 2016 May; 80():50-8. PubMed ID: 26826559
[TBL] [Abstract][Full Text] [Related]
5. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Claesen K; Mertens JC; Leenaerts D; Hendriks D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
[TBL] [Abstract][Full Text] [Related]
6. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Leenaerts D; Bosmans JM; van der Veken P; Sim Y; Lambeir AM; Hendriks D
J Thromb Haemost; 2015 Dec; 13(12):2227-32. PubMed ID: 26340515
[TBL] [Abstract][Full Text] [Related]
8. Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture.
Roth L; Van Dam D; Van der Donckt C; Schrijvers DM; Lemmens K; Van Brussel I; De Deyn PP; Martinet W; De Meyer GR
Physiol Behav; 2015 Feb; 139():397-402. PubMed ID: 25449385
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.
Mertens JC; Claesen K; Leenaerts D; Sim Y; Lambeir AM; Hendriks D
J Thromb Haemost; 2019 Jun; 17(6):878-884. PubMed ID: 30887647
[TBL] [Abstract][Full Text] [Related]
10. ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation.
Claesen K; De Loose J; Van Wielendaele P; De Bruyn E; Sim Y; Thys S; De Meester I; Hendriks D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835137
[TBL] [Abstract][Full Text] [Related]
11. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
Silveira A; Schatteman K; Goossens F; Moor E; Scharpé S; Strömqvist M; Hendriks D; Hamsten A
Thromb Haemost; 2000 Sep; 84(3):364-8. PubMed ID: 11019956
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.
Claesen K; Sim Y; Bracke A; De Bruyn M; De Hert E; Vliegen G; Hotterbeekx A; Vujkovic A; van Petersen L; De Winter FHR; Brosius I; Theunissen C; van Ierssel S; van Frankenhuijsen M; Vlieghe E; Vercauteren K; Kumar-Singh S; De Meester I; Hendriks D
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329820
[TBL] [Abstract][Full Text] [Related]
13. Acetylsalicylic Acid Reduces Passive Aortic Wall Stiffness and Cardiovascular Remodelling in a Mouse Model of Advanced Atherosclerosis.
Roth L; Rombouts M; Schrijvers DM; Emini Veseli B; Martinet W; De Meyer GRY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008828
[TBL] [Abstract][Full Text] [Related]
14. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
[TBL] [Abstract][Full Text] [Related]
15. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
Mertens JC; Leenaerts D; Brouns R; Engelborghs S; Ieven M; De Deyn PP; Lambeir AM; Hendriks D
J Thromb Haemost; 2018 Feb; 16(2):342-348. PubMed ID: 29194929
[TBL] [Abstract][Full Text] [Related]
16. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
Brouns R; Heylen E; Sheorajpanday R; Willemse JL; Kunnen J; De Surgeloose D; Hendriks DF; De Deyn PP
Clin Neurol Neurosurg; 2009 Feb; 111(2):165-70. PubMed ID: 18980797
[TBL] [Abstract][Full Text] [Related]
17. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
[TBL] [Abstract][Full Text] [Related]
18. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.
Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
Thromb Haemost; 1999 Dec; 82(6):1718-21. PubMed ID: 10613660
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Mertens JC; Boisseau W; Leenaerts D; Di Meglio L; Loyau S; Lambeir AM; Ducroux C; Jandrot-Perrus M; Michel JB; Mazighi M; Hendriks D; Desilles JP
J Thromb Haemost; 2020 Dec; 18(12):3325-3335. PubMed ID: 32869423
[TBL] [Abstract][Full Text] [Related]
20. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
